[go: up one dir, main page]

KR940005274A - 쇼그렌(Sjoegren)증후군 치료제 - Google Patents

쇼그렌(Sjoegren)증후군 치료제 Download PDF

Info

Publication number
KR940005274A
KR940005274A KR1019930012594A KR930012594A KR940005274A KR 940005274 A KR940005274 A KR 940005274A KR 1019930012594 A KR1019930012594 A KR 1019930012594A KR 930012594 A KR930012594 A KR 930012594A KR 940005274 A KR940005274 A KR 940005274A
Authority
KR
South Korea
Prior art keywords
addition salt
sjogren
syndrome
syndrome treatment
oxathioran
Prior art date
Application number
KR1019930012594A
Other languages
English (en)
Other versions
KR100331046B1 (ko
Inventor
노부아끼 아베
야스요시 다께시다
Original Assignee
쑈노 가쯔야
유끼지루시유꼬 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16540522&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR940005274(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 쑈노 가쯔야, 유끼지루시유꼬 가부시끼가이샤 filed Critical 쑈노 가쯔야
Publication of KR940005274A publication Critical patent/KR940005274A/ko
Application granted granted Critical
Publication of KR100331046B1 publication Critical patent/KR100331046B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

[구성]스피로옥사티오란퀴누클리딘유도체 또는 그 산부가염을 유효성분으로 하는 쇼그렌증후군치료제.
[효과]2-메틸스피로(1,3-옥사티오란-5,3')퀴누클리딘염산부가염을 쓰면 쇼그렌증후군을 치료할수가 있다. 구체적으로는 구내건조증, 눈안의 건조증 또는 건조성각막염등의 병태를 개선 또는 치료할수가 있다.
[선택도]없음

Description

쇼그렌(Sjoegren)증후군 치료제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 실시예(2)의 방법에 의한 퀴누클리딘염산부가염(식Ⅱ)투여후 방치시간과 침분비량의 관계를 나타낸다.

Claims (3)

  1. 다음의 일반식(Ⅰ)로써 표시되는 스피로옥사티오란퀴누클리딘유도체 또는 그 산부가염을 유효성분으로 하는 쇼그렌증후군치료제.
    [식중, Z는) CR1, R2또는 두개의 수소원자이고, R1및 R2는 동일하거나 달라도 좋고, 각각 알킬, 시크로벤틸, 시크로헥실, 아릴 또는 디아릴메티롤 또는 1개 이상의 아릴기로 치환된 알킬로서 R1과 R2의 어느쪽이나 한쪽이 수소이어도 좋다).
  2. 제1항에 있어서, 스피로옥사티오란 퀴노클리딘유도체 산부가염이 다음의 화학식(Ⅱ)로 표시되는 2-메틸스피로(1,3-옥사티오란-5,3')퀴누클리딘 염산부가염인 쇼그렌증후군치료제.
  3. 제2항에 있어서, 2-메틸스피로(1,3-옥사티오란-5,3')퀴누클리딘염산부가염인 쇼그렌증후군치료제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930012594A 1992-07-10 1993-07-06 쇼그렌증후군치료제 KR100331046B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4207485A JP2683783B2 (ja) 1992-07-10 1992-07-10 シェーグレン症候群治療剤
JP92-207485 1992-07-10

Publications (2)

Publication Number Publication Date
KR940005274A true KR940005274A (ko) 1994-03-21
KR100331046B1 KR100331046B1 (ko) 2002-08-19

Family

ID=16540522

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930012594A KR100331046B1 (ko) 1992-07-10 1993-07-06 쇼그렌증후군치료제

Country Status (15)

Country Link
US (1) US5340821A (ko)
EP (1) EP0578511B1 (ko)
JP (1) JP2683783B2 (ko)
KR (1) KR100331046B1 (ko)
AT (1) ATE184483T1 (ko)
AU (1) AU666734B2 (ko)
CA (1) CA2099970C (ko)
DE (1) DE69326395T2 (ko)
DK (1) DK0578511T3 (ko)
ES (1) ES2138613T3 (ko)
IL (1) IL106218A (ko)
NO (1) NO303765B1 (ko)
NZ (1) NZ248099A (ko)
TW (1) TW230750B (ko)
ZA (1) ZA934883B (ko)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2852608B2 (ja) * 1994-06-27 1999-02-03 雪印乳業株式会社 口腔乾燥症治療剤
US6140374A (en) * 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
JP4447685B2 (ja) * 1999-01-14 2010-04-07 第一三共株式会社 皮膚乾燥症治療剤
US20110150974A1 (en) * 2004-08-06 2011-06-23 Daiichi Pharmaceutical Co., Ltd. Agent For Oral Mucosal Administration
JP2006070027A (ja) * 2004-08-06 2006-03-16 Dai Ichi Seiyaku Co Ltd 口腔粘膜投与剤
AU2005290532A1 (en) * 2004-10-05 2006-04-13 Astellas Pharma Inc. Pharmaceutical composition for xerophthalmia and xerostomia treatment
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
MX2009002496A (es) 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8143400B2 (en) * 2008-01-10 2012-03-27 Apotex Pharmachem Inc. Process for the preparation and purification of cis-2-methylspiro(1,3-oxathiolane-5,3′)quiniclidine hydrochloride
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
MX2012005456A (es) 2009-11-12 2012-06-19 Acacia Pharma Ltd Uso de betanecol para el tratamiento de xerostomia.
GB201107533D0 (en) 2011-05-06 2011-06-22 Acacia Pharma Ltd Formulaiton
CN102846607A (zh) * 2012-04-09 2013-01-02 珠海亿邦制药股份有限公司 一种以盐酸西维美林为活性成分的固体制剂及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001396A (en) * 1971-08-04 1977-01-04 Chinoin Pharmaceutical And Chemical Works Ltd. Hormonal product extracted from parathyroid gland and process for the preparation thereof
US4110441A (en) * 1974-04-29 1978-08-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Gamma-l-glutamyl cholamine phosphate
US4100271A (en) * 1976-02-26 1978-07-11 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4701450A (en) * 1984-03-21 1987-10-20 Akzo N.V. Steroids for use as immunomodulators
US4855290A (en) * 1985-05-10 1989-08-08 State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research Derivatives of quinuclidine
US4684727A (en) * 1985-07-29 1987-08-04 Schering Corporation Zwitterionic 1,8-naphthyridine and pyrazino[2,3-b]pyridine containing compounds useful as anti-allergic, anti-inflammatory and cycloprotective agents
ZA868369B (en) * 1986-01-10 1987-11-25 Israel State Derivatives of quinuclidine
GB8717446D0 (en) * 1987-07-23 1987-08-26 Merck Sharp & Dohme Chemical compounds
US4876260A (en) * 1987-10-28 1989-10-24 State Of Israel, Israel Institute Of Biological Research Oxathiolanes
CA1303503C (en) * 1987-11-10 1992-06-16 Marc Plamondon Ophthalmic solution comprising iodine-polyvinylpyrrolidone complex
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
US4997654A (en) * 1989-08-14 1991-03-05 Warner-Lambert Company Method for increasing salivation for xerostomia patients
EP0499313B1 (en) * 1991-02-11 1997-06-11 MERCK SHARP & DOHME LTD. Azabicyclic compounds, pharmaceutical compositions containing them and their use in therapy

Also Published As

Publication number Publication date
TW230750B (ko) 1994-09-21
CA2099970A1 (en) 1994-01-11
EP0578511B1 (en) 1999-09-15
NO303765B1 (no) 1998-08-31
IL106218A (en) 1997-02-18
JP2683783B2 (ja) 1997-12-03
AU666734B2 (en) 1996-02-22
JPH0624981A (ja) 1994-02-01
ZA934883B (en) 1994-02-03
DK0578511T3 (da) 2000-04-03
NZ248099A (en) 1999-07-29
ES2138613T3 (es) 2000-01-16
AU4181993A (en) 1994-01-13
IL106218A0 (en) 1993-11-15
CA2099970C (en) 2003-12-30
KR100331046B1 (ko) 2002-08-19
DE69326395T2 (de) 2000-04-20
EP0578511A1 (en) 1994-01-12
US5340821A (en) 1994-08-23
ATE184483T1 (de) 1999-10-15
NO932520L (no) 1994-01-11
DE69326395D1 (de) 1999-10-21
NO932520D0 (no) 1993-07-09

Similar Documents

Publication Publication Date Title
KR940005274A (ko) 쇼그렌(Sjoegren)증후군 치료제
KR940007022A (ko) 피패리딘 유도체, 이것의 제법 및 치료에 있어서 이것의 이용
KR950017957A (ko) 3, 4, 4-삼치환-피페리디닐-n-알킬카르복실레이트의 제법 및 중간체
KR910011896A (ko) 신규한 글리코펩티드 유도체
DE3271269D1 (en) Benzimidazole derivatives, process for the preparation thereof and pharmaceutical composition containing the same
KR900003163A (ko) 시클로헥산 유도체
KR960007592A (ko) 신규한 피롤로카바졸
KR950016727A (ko) 트롬보모듈린 발현을 증가시키는 방법
KR900004658A (ko) 이치환 벤질아민, 그의 제조방법, 약제로서의 그의 용도 및 그의 합성 약제
KR890005088A (ko) 4- 아미노피리딘 유도체 및 그의 산 부가염
KR890011596A (ko) 불면증 치료용 의약품의 제조에 있어서 1,4-이치환-피페리디닐 화합물의 용도
KR890007730A (ko) 허혈성 심질환 치료제
KR900009606A (ko) 불소-함유 2-니트로 이미다졸 유도체 및 그를 함유하는 방사선 증감제
KR910004191A (ko) 신질환치료제
KR890014480A (ko) 2-피리딜아세트산 유도체, 이의 제조방법 및 이를 함유하는 약제학적 조성물
KR890008136A (ko) 항균성 9-데옥소-9a-알릴 및 프로파길-9a-아자-9a-호모에리트로 마이신 A 유도체
KR950703341A (ko) 항부정맥제
KR880002822A (ko) 뇌허혈증 예방 치료제
KR880001596A (ko) 디하이드로피리딘 화합물-함유 뇌기능이상 치료제
KR870006035A (ko) 신규 항균제 1-티에닐-4-옥소퀴놀린-3-카복실산 화합물의 제법
KR950010896A (ko) 근시의 예방 및 치료용 조성물
KR890003755A (ko) 7- (2- 메틸- 4- 아미노피롤리디닐)나프티리딘 및 퀴놀린 화합물
KR850005228A (ko) 살균제인 아미노알칸포스폰산 및 그 유도체
KR910016692A (ko) 신규 8-술파밀메틸렌-2-아미노 테트랄린
KR900018083A (ko) 에폭시숙신산 유도체

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19930706

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19980423

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19930706

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20000214

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20001030

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20000214

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20001130

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20001030

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20011231

Appeal identifier: 2000101002837

Request date: 20001130

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20001130

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20001130

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20000410

Patent event code: PB09011R02I

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20010221

Patent event code: PE09021S01D

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20011231

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20010129

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20020130

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20020320

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20020320

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20041223

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20060131

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20070205

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20080214

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20090311

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20100310

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20110223

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20120223

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20130227

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20130227

Start annual number: 12

End annual number: 12

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20140106

Termination category: Expiration of duration